Travere Therapeutics (TVTX) stock is in focus as the company inks a licensing deal worth up to $1.1B with China’s Everest ...

June 2 (Reuters) - Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization ...

The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the ...

Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic. The deal, ...

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to ...

Healthcare equities are widely viewed as classic defensive holdings that can cushion portfolios amid shifting market cycles, ...